Bye-bye Bayh: Pharm Industry Critics are Abusing a Law

Here we go again. 

The Build Back Better bill hit a dead end in the U.S. Senate last year, thanks in part to a host of harmful drug pricing schemes included in the trillion-dollar plan. 

But the assault on pharmaceutical innovation continues, through the front door of Congress and the back door of the bureaucracy.